Biokine Therapeutics
Company Details
Status: Private
Employees: 11-50
Location:
Rehovot, Israel
Type:
sample
Technology:
sample
sample
sample
sample
About: Biokine Therapeutics is a private biopharmaceutical company founded in 2000. Biokine lead product BKT140/BL8040, is a high affinity, long-acting CXCR4 receptor inhibitor that already passed successful Phase III for Stem Cell Mobilization and Phase I/II for Immunotherapy for cancer together with immune check point inhibitor Pembrolizumab (Keytruda, Merck) and Atezolizumab (Tecentriq, Genentech/Roche). BL8040 was licensed to BiolineRx and is being developed in the clinic together with BiolineRx Ltd. (NASDAQ:BLRX). Biokine has also developed a suite of unique technologies, MigHit™ – which is a phenotypic screen that allows identification of small molecules targeting migration and survival pathways in cancer and ImmunHit™ which is platform technology enables identification of small molecules targeting IFN-g mediated immune response in cancer and inflammation.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Biokine Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.